GE Healthcare Presents Parkinsonian Syndromes and Alzheimer’s Disease Research Data and Introduces New Products at Society of Nuclear Medicine and Molecular Imaging Annual Meeting
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
GE Healthcare today announced that results from three company studies utilizing DaTscan™ (Ioflupane I 123 Injection) in Parkinsonian Syndromes or the investigational imaging agent [18F]flutemetamol will be presented at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI 2013) taking place in Vancouver from June 8-11.
Help employers find you! Check out all the jobs and post your resume.
GE Healthcare today announced that results from three company studies utilizing DaTscan™ (Ioflupane I 123 Injection) in Parkinsonian Syndromes or the investigational imaging agent [18F]flutemetamol will be presented at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI 2013) taking place in Vancouver from June 8-11.
Help employers find you! Check out all the jobs and post your resume.